Trientine Pregnancy and Breastfeeding Warnings
Medically reviewed by Drugs.com. Last updated on Dec 5, 2022.
Trientine Pregnancy Warnings
This drug should not be used during pregnancy unless the benefit outweighs the risk to the fetus.
US FDA pregnancy category: C
Comments:
-Monitor during pregnancy for fetal abnormalities and maternal serum copper.
-Adjust dose to maintain serum copper levels in the normal range.
Animal studies showed teratogenicity (resorptions, fetal abnormalities, hemorrhage, and edema) at doses similar to human doses. There are no controlled data in human pregnancy.
US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
Trientine Breastfeeding Warnings
Caution is recommended.
Excreted into human milk: Unknown
Excreted into animal milk: Data not available
Comments:
-Monitor babies for serum copper and ceruloplasmin levels where appropriate.
-This drug has a low molecular weight and excretion into breast milk is expected.
See also
References for pregnancy information
- Product Information. Syprine (trientine). Aton Pharma. 2001.
- Cerner Multum, Inc. UK Summary of Product Characteristics.
References for breastfeeding information
- Product Information. Syprine (trientine). Aton Pharma. 2001.
- Cerner Multum, Inc. UK Summary of Product Characteristics.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.